Drug Royalties Co. Ramps Up Issuance

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

  • 30 Nov 2012

Ontario-based DRI Capital is preparing a securitization from its portfolio of royalties from pharmaceutical and bio-tech patents, following up its March ABS issuance and marking an accelerated issuance strategy for the company.

DRI planned to tap the ABS market for financing in August of 2011, but shelved the ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 BNP Paribas 12,508 23 18.18
2 Bank of America Merrill Lynch (BAML) 8,059 25 11.72
3 Lloyds Bank 5,761 18 8.38
4 Citi 5,606 15 8.15
5 JP Morgan 5,007 7 7.28

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 94,444.52 266 11.16%
2 Bank of America Merrill Lynch 79,057.17 220 9.35%
3 Wells Fargo Securities 69,655.75 196 8.23%
4 JPMorgan 69,110.65 196 8.17%
5 Credit Suisse 56,930.26 144 6.73%